ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Voriconazole

Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.

Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.

Drug pageVoriconazole: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 31, 200523 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only200 open or runningphase 4since Aug 31, 2005Aug 25, 2005none ahead
Yung Shin Pharm. Ind.its history only20 open or runningphase 4since Sep 21, 2016Sep 21, 2016none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 1since Dec 13, 2015Dec 13, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2015First study: phase 1 study in AspergillosisFirst studyNCT02631954 · 24 enrolled · Korea, Republic of

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

The one study Chong Kun Dang Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02631954Aspergillosis · Korea, Republic of1CompletedOct 201524

How it is read

Names in the registry

  • “Voriconazole”, 13 entries
  • “voriconazole”, 7 entries
  • “voriconazole (Vfend)”, 3 entries
  • “oral voriconazole”, 1 entry
  • “Vaway”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.